Literature DB >> 16050864

The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.

Jeffrey J Glasheen1, Randolph V Fugit, Allan V Prochazka.   

Abstract

BACKGROUND: Medication interactions account for a significant proportion of overanticoagulation in warfarin users. However, little is known about the incidence or degree of interaction with commonly used oral antibiotics.
OBJECTIVE: To investigate the incidence and degree of overanticoagulation associated with commonly used oral antibiotics.
DESIGN: Retrospective cohort study of patients using warfarin who initiated an antibiotic (azithromycin, levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin for clinical indications between January 1998 and December 2002. The incidence of international normalized ratio (INR) elevation and the degree of change and bleeding events after institution of either medication type was recorded.
SUBJECTS: Patients at a university-affiliated Veteran's Affairs Medical Center.
RESULTS: The mean change in INR was -0.15 for terazosin, 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean INR changes in the antibiotic groups were all statistically different from the terazosin group. The incidence of supratherapeutic INR was 5% for terazosin, 31% for azithromycin, 33% for levofloxacin, and 69% for TMP/SMX. The incidence of absolute INR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for levofloxacin, and 44% for TMP/SMX.
CONCLUSIONS: Among acutely ill outpatients, oral antibiotics (azithromycin, levofloxacin, and TMP/SMX) increase the incidence and degree of overanticoagulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050864      PMCID: PMC1490169          DOI: 10.1111/j.1525-1497.2005.0136.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  16 in total

1.  Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy--a comment.

Authors:  Jeffrey J Glasheen; Randolph V Fugit; Allan V Prochazka
Journal:  Pharmacotherapy       Date:  2003-08       Impact factor: 4.705

2.  Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin.

Authors:  N P Beckey; D Parra; A Colon
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

Review 3.  Hemorrhagic complications of anticoagulant treatment.

Authors:  M N Levine; G Raskob; S Landefeld; C Kearon
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

4.  Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy.

Authors:  Weeranuj Yamreudeewong; Dennis L Lower; David M Kilpatrick; Ann M Enlow; Margo M Burrows; Mark C Greenwood
Journal:  Pharmacotherapy       Date:  2003-03       Impact factor: 4.705

5.  Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.

Authors:  F J Penning-van Beest; E van Meegen; F R Rosendaal; B H Stricker
Journal:  Clin Pharmacol Ther       Date:  2001-06       Impact factor: 6.875

6.  Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.

Authors:  S Liao; M Palmer; C Fowler; R K Nayak
Journal:  J Clin Pharmacol       Date:  1996-11       Impact factor: 3.126

Review 7.  Warfarin therapy: evolving strategies in anticoagulation.

Authors:  J D Horton; B M Bushwick
Journal:  Am Fam Physician       Date:  1999-02-01       Impact factor: 3.292

8.  Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin.

Authors:  S Panneerselvam; C Baglin; W Lefort; T Baglin
Journal:  Br J Haematol       Date:  1998-11       Impact factor: 6.998

Review 9.  Interactions of warfarin with drugs and food.

Authors:  P S Wells; A M Holbrook; N R Crowther; J Hirsh
Journal:  Ann Intern Med       Date:  1994-11-01       Impact factor: 25.391

10.  Optimal oral anticoagulant therapy in patients with mechanical heart valves.

Authors:  S C Cannegieter; F R Rosendaal; A R Wintzen; F J van der Meer; J P Vandenbroucke; E Briët
Journal:  N Engl J Med       Date:  1995-07-06       Impact factor: 91.245

View more
  26 in total

1.  High-risk antimicrobial prescriptions among ambulatory patients on warfarin.

Authors:  M A Lane; S T Devine; J R McDonald
Journal:  J Clin Pharm Ther       Date:  2011-04-24       Impact factor: 2.512

2.  [Management and therapy of atrial fibrillation in geriatric patients].

Authors:  M Gosch; R E Roller; B Böhmdorfer; U Benvenuti-Falger; B Iglseder; M Lechleitner; U Sommeregger; P Dovjak
Journal:  Z Gerontol Geriatr       Date:  2012-01       Impact factor: 1.281

3.  Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.

Authors:  Michael A Lane; Angelique Zeringue; Jay R McDonald
Journal:  Am J Med       Date:  2014-03-19       Impact factor: 4.965

4.  Acute renal failure caused by severe coagulopathy induced by the interaction between warfarin potassium and levofloxacin: a case report.

Authors:  Chiaki Nemoto; Yukihiro Ikegami; Jiro Shimada; Yasuhiko Tsukada; Yoshinobu Abe; Choichiro Tase
Journal:  J Anesth       Date:  2012-08-09       Impact factor: 2.078

5.  Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.

Authors:  Jacques Baillargeon; Holly M Holmes; Yu-Li Lin; Mukaila A Raji; Gulshan Sharma; Yong-Fang Kuo
Journal:  Am J Med       Date:  2012-02       Impact factor: 4.965

6.  Prescribing warfarin appropriately to meet patient safety goals.

Authors:  Lekshmi Dharmarajan; T S Dharmarajan
Journal:  Am Health Drug Benefits       Date:  2008-07

7.  Oral anticoagulation in the hospital: analysis of patients at risk.

Authors:  Nancy L Dawson; Dusko Klipa; Angela K O'Brien; Julia E Crook; Melanie W Cucchi; Alden K Valentino
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

8.  Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism.

Authors:  Xiaowei Gong; Haiyan Wang; Yadong Yuan
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

9.  Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin.

Authors:  Abrar Ahmed; John C Stephens; Carol A Kaus; William P Fay
Journal:  J Thromb Thrombolysis       Date:  2007-11-06       Impact factor: 2.300

Review 10.  Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.

Authors:  Michael Makris; Joost J van Veen; Rhona Maclean
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.